Pfizer (PFE)
(Delayed Data from NYSE)
$29.50 USD
+0.40 (1.37%)
Updated Jul 16, 2024 04:01 PM ET
Pre-Market: $29.34 -0.16 (-0.54%) 9:24 AM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.50 USD
+0.40 (1.37%)
Updated Jul 16, 2024 04:01 PM ET
Pre-Market: $29.34 -0.16 (-0.54%) 9:24 AM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
by Zacks Equity Research
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
by Zacks Equity Research
Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
by Zacks Equity Research
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.
The Zacks Analyst Blog Highlights Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet
by Zacks Equity Research
Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet are included in this Analyst Blog.
Top Stock Reports for Amazon.com, Visa & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Visa Inc. (V) and Pfizer Inc. (PFE).
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
by Kinjel Shah
Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.
Here's Why Pfizer (PFE) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Company News for May 2, 2024
by Zacks Equity Research
Companies In The News Are: CVS, PFE, PPL, ADP.
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
by Zacks Equity Research
Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue expectations.
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 46.43% and 7.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
by Zacks Equity Research
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
Eli Lilly (LLY) Tops Q1 Earnings Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 1.98% and 0.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
by Kinjel Shah
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
Why Pfizer (PFE) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What Makes Amazon (AMZN) Attractive Ahead of Q1 Earnings?
by Tirthankar Chakraborty
Sustained growth in advertising business and acceleration in AWS make Amazon (AMZN) an enticing buy heading into its first-quarter earnings release.
Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
by Sweta Killa
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.